FOCUS on New Drug Approvals. The FDA just announced approval of Revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children with relapsed
FOCUS on Drug Failures. The FDA rejected Biohaven’s glutamate modulator Troriluzole for treatment of spinocerebellar ataxia, a rare and life-threatening neurodegenerative disease with no treatment options.
FOCUS on SIRT6. Sirtuin 6 (SIRT6) is an NAD-dependent histone deacetylase shown to function as a tumor suppressor in several cancer types. However, the therapeutic potential
FOCUS on CRISPR. October 20 is World CRISPR day, celebrating this powerful gene-editing technology. FOCUS Biomolecules offers a large variety of small molecules used to enhance
FOCUS on boosting tumor immunogenicity. In a paper just out in PNAS, researchers at UMass Chan Medical School report that PPT1 (Palmitoyl Protein Thioesterase 1) is
FOCUS on Neuroblastoma. In a paper just out in Nature Communications, Singh et al. report: “To better understand the cellular plasticity of neuroblastoma in chemoresistance, we
BOGO
